- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology-08-02-2009
Pharmaceutical Technology
Q&A with Peter Soelkner, managing director of Vetter Pharma International
August 10, 2009
Industry Leaders: Q&A
33
8
Soelkner discusses the latest industry developments and trends.
Shifting Fortunes in API Market Growth
August 02, 2009
Ingredients Insider
33
8
Biologics enhance their positions amidst slowing growth in the global and US markets.
Inside PIC/S: South Africa's Accession to PIC/S
August 02, 2009
Inside PIC/S
33
8
South Africa was the first country on the African continent to become a PIC/S member. The country's Director of Inspectorate and Law Enforcement describes the 10-year process.
Step Carefully into Foreign Affairs
August 02, 2009
Outsourcing Outlook
33
8
As the pharmaceutical industry looks to emerging markets, corruption becomes an important issue.
In the Spotlight August 2009
August 02, 2009
In the Spotlight
33
8
Editors' Picks of Pharmaceutical Science & Technology Innovations
For Biotherapeutics, Innovation is Not Enough
August 02, 2009
PharmTech Talk
33
8
Biotech firms must first close the gaps between science and biology on the path toward QbD.
Formulation and Process Optimization of Cinnarizine Fast-Release Tablets
August 02, 2009
Peer-Reviewed Research
33
8
The authors prepared granules containing cinnarizine using polyethylene glycol 6000 as a melting binder and lactose monohydrate as hydrophilic filler. The effects of binder concentration and size were studied.
Pharma-Biotech Partnerships: Lessons for Personalized Medicine
August 02, 2009
Viewpoint
33
8
Big Pharma entered biotech too late. That same mistake can be avoided in personalized medicine.
Colder Drugs Will Prevail
August 02, 2009
Packaging Forum
33
8
An expanding number of products and services plug gaps in the cold chain. This article contains bonus online-exclusive material.
A Dubious Foundation for Quality Control
August 02, 2009
Online Exclusives
33
8
The author of an ambitious book about quality control falls short of reaching his goals.
Comparison of Authentic and Suspect Pharmaceuticals
August 02, 2009
Peer-Reviewed Research
33
8
The authors applied near-infrared (NIR) spectrophotometry to assess whether eight drug products were authentic or counterfeit.
More Than You Need to Know about Manufacturing Pharmaceutical Proteins
August 02, 2009
Online Exclusives
33
8
The author of a book about biopharmaceutical production includes irrelevant information.
Of Hubris and Happy Endings
August 02, 2009
From The Editor
33
8
Individuals and companies at the top seem to have no problem short-circuiting their success.
Insider Solutions: Preventing the Next Heparin Scare
August 02, 2009
Insider Solutions
33
8
Determined to prevent further supply-chain breaches, industry takes charge, offers proposals.
Pharma Girds for Healthcare Reform
August 02, 2009
Washington Report
33
8
Pressure to reduce healthcare spending has put drug rebates, price cuts, and tax hikes on the table.
Bio Burdens
August 02, 2009
Agent-In-Place
33
8
An ounce of contamination usually leads to a mountain of investigation.
FDA Perspectives: An Overview of the CDER Drug Recall Root Cause Research Project
August 02, 2009
Peer-Reviewed Research
33
8
This article provides an overview of the drug Recall Root Cause Research (RRCR) project, an initiative of the US Food and Drug Administration's Center for Drug Evaluation and Research.
Big Pharma Tightens Its Belt in Global Manufacturing
August 02, 2009
Special Report
33
8
In the aftermath of recent restructuring, Big Pharma is sporting a reduced global manufacturing footprint while intensifying its focus to biologics and emerging markets. What will be the look of tomorrow's manufacturing networks?
Report From: China
July 28, 2009
News
33
8
China's State Food and Drug Administration has completed a new draft of GMP guidelines, but after a series of quality-control events, it will take time for the country to regain the global pharmaceutical industry's trust.